{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:54:16Z","timestamp":1783335256376,"version":"3.54.6"},"reference-count":26,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.nrleng.2020.07.008","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:12:45Z","timestamp":1602234765000},"page":"628-632","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology\u2019s Headache Study Group"],"prefix":"10.1016","volume":"35","author":[{"given":"N.","family":"Moroll\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Belv\u00eds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Dios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Pag\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Gonz\u00e1lez-Oria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Latorre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Santos-Lasaosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2020.07.008_bib0005","doi-asserted-by":"crossref","unstructured":"Bolay H, G\u00fcl A, Baykan B. COVID-19 is a real headache! Headache. https:\/\/doi.org\/10.1111\/head.13856. [published online ahead of print, 2020 May 15].","DOI":"10.1111\/head.13856"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0010","doi-asserted-by":"crossref","first-page":"311","DOI":"10.33588\/rn.7009.2020179","article-title":"Neurological complications of coronavirus and COVID-19","volume":"70","author":"Carod-Artal","year":"2020","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0015","doi-asserted-by":"crossref","unstructured":"Belvis R. Headaches during COVID-19: my clinical case and review of the literature. Headache. https:\/\/doi.org\/10.1111\/head.13841. [published online ahead of print, 2020 May 15].","DOI":"10.1111\/head.13841"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0020","series-title":"Guidelines of the Spanish Society of Neurology for the diagnoses and treatment of headaches","author":"Ezpeleta","year":"2015"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0025","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0030","doi-asserted-by":"crossref","first-page":"F398","DOI":"10.1152\/ajprenal.90488.2008","article-title":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan","volume":"296","author":"Soler","year":"2009","journal-title":"Am J Physiol Ren Pysiol"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0035","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.yjmcc.2016.05.012","article-title":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-mas axes in pressure overload-induced cardiac remodeling in male mice","volume":"97","author":"Wang","year":"2016","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s10194-020-01106-5","article-title":"Headache medication and the COVID-19 pandemic","volume":"21","author":"MaassenVanDenBrink","year":"2020","journal-title":"J Headache Pain"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0045","unstructured":"American Heart Association, Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. Available from: https:\/\/newsroom.heart.org\/news\/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0050","unstructured":"European Society of Hypertension, https:\/\/www.eshonline.org\/spotlights\/eshstabtement-on-covid-19\/."},{"key":"10.1016\/j.nrleng.2020.07.008_bib0055","series-title":"Could Ibuprofen Worsen Disease for People With COVID-19?","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0060","unstructured":"European Medicines Agency. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic."},{"key":"10.1016\/j.nrleng.2020.07.008_bib0065","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0070","unstructured":"Food and Drug Administration. FDA Advises Patients on Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for COVID-19. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-advises-patients-use-non-steroidal-anti-inflammatory-drugs-nsaids-covid-19."},{"key":"10.1016\/j.nrleng.2020.07.008_bib0075","unstructured":".Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. La AEMPS informa que ning\u00fan dato indica que el ibuprofeno agrave las infecciones por COVID-19. Available from: https:\/\/www.aemps.gob.es\/informa\/notasinformativas\/medicamentosusohumano-3\/2020-medicamentosusohumano-3\/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19\/"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0080","author":"European Medicines Agency"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0085","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000375362","article-title":"Ibuprofen attenuates cardiac fibrosis in streptozotocin induced diabetic rats","volume":"131","author":"Qiao","year":"2015","journal-title":"Cardiology"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0090","unstructured":"Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19). 2020. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/hcp\/clinicalguidance_management_patients."},{"key":"10.1016\/j.nrleng.2020.07.008_bib0095","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0100","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(19)30417-5","article-title":"Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial","volume":"8","author":"Villar","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S1473-3099(13)70204-4","article-title":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study","volume":"13","author":"Assiri","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0110","article-title":"Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single center cohort of kidney recipients","volume":"10","author":"Montagud-Marrahi","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0115","article-title":"First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study","volume":"10","author":"Tschopp","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0120","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S1474-4422(20)30147-2","article-title":"Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis","volume":"19","author":"Sormani","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2020.07.008_bib0125","unstructured":"Wang N. First Affiliated Hospital of Fujian Medical University. Fingolimod en COVID-19. ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04280588."},{"key":"10.1016\/j.nrleng.2020.07.008_bib0130","series-title":"Manual Covid-19 para el neur\u00f3logo general","author":"Ezpeleta","year":"2020"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580820302170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580820302170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:32:16Z","timestamp":1761881536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580820302170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2173580820302170"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.07.008","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology\u2019s Headache Study Group","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2020.07.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}